Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Seeks Japan Approval for Low-Dose Revestive
November 29, 2021
- Sanofi’s Pompe Disease Drug Nexviazyme Now Available in Japan
November 29, 2021
- AbbVie Japan Rolls Out New Dosage Forms for Rinvoq, Skyrizi
November 29, 2021
- Daiichi Sankyo Sets Up New Subsidiaries in 3 Countries
November 29, 2021
- Takeda’s GI Biz Poised for Growth with 3 Products Now in Its Lineup
November 29, 2021
- MSD Japan Hails Resumption of HPV Vaccine Recommendation
November 29, 2021
- Shionogi, Vietnam Discuss Tech Transfer of COVID-19 Vaccine
November 26, 2021
- J-TEC to Start Study of Allogeneic Cultured Epidermis for DDB Patients
November 26, 2021
- Kowa Files Glanatec Combo for Glaucoma, Ocular Hypertension in Japan
November 26, 2021
- AstraZeneca’s Lupus Med, 3rd Humira Biosimilar Now Available in Japan
November 26, 2021
- Shionogi Pharma, 5 Other Firms to Form Continuous Manufacturing JV
November 25, 2021
- Top 3 Japan Generic Makers Face Uphill Struggle Overseas in April-September: Jiho Tally
November 25, 2021
- Japan Biz of Top 3 Generic Makers in H1 Impacted by GMP Issues, Substitution Demand: Jiho Tally
November 25, 2021
- Takeda’s CMV Drug Livtencity Bags US Approval
November 25, 2021
- Sosei Out-Licenses Neuropsychiatric Assets to Neurocrine
November 24, 2021
- Alnylam to File Its Third Drug in Japan 3 Years after Market Entry, Eyes CNS Therapies
November 24, 2021
- Top 4 Wholesalers’ Average Operating Margin at 0.46% on Tough Price Negotiations: H1 FY2021 Earnings
November 22, 2021
- Sales Reps’ Detailing Activities Rise 1.5% in September, but Remain in Doldrums: Intage
November 22, 2021
- Daiichi Sankyo Begins PIII for TROP2 ADC in Second-Line Breast Cancer
November 22, 2021
- Quizartinib Shows OS Benefit in Frontline AML, Daiichi Sankyo Mulls US/EU Filing
November 22, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…